NCT02446171View on ClinicalTrials.gov

A Bioavailability Study With Alternate Methods of Administration of Naloxegol Tablets, and Solution

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
BioavailabilityHealthy Subjects
Interventions
DRUG

Naloxegol 25 mg tablet, crushed, suspended in water, given orally

naloxegol 25 mg (1 tablet) crushed, suspended in water, given orally

DRUG

Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube

naloxegol 25 mg (1 tablet) crushed, suspended in water, given via nasogastric tube

DRUG

Naloxegol 25 mg (10 mL oral solution)

naloxegol 25 mg (10 mL oral solution)

DRUG

Naloxegol 25 mg tablet, given orally

naloxegol 25 mg (1 tablet) whole tablet, given orally

Trial Locations (1)

Unknown

Research Site, Berlin

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY